The core component of Octreotide Acetate Solution is Octreotide Acetate, an artificially synthesized octapeptide derivative with a chemical structure optimized based on natural somatostatin. Its molecular formula is C ₅₁ H ₇₀ N ₁₀ O ₁₂ S ₂, with a molecular weight of approximately 1019.3 g/mol. Octreotide connects two cysteine residues (Cys ² - Cys ⁷) through a disulfide bond, forming a stable cyclic structure that endows it with stronger receptor affinity and a longer in vivo half-life (approximately 1.7-2 hours). This substance usually exists in the form of an injection, including ready to use injections that are pre packaged in ampoules or syringes at concentrations of 50 μ g/mL, 100 μ g/mL, 200 μ g/mL, or 500 μ g/mL. Freeze dried powder injections also require reconstitution with physiological saline or specialized solvents before use, with common specifications of 0.1 mg, 0.2 mg, or 0.5 mg. Long acting formulations such as microspheres or liposomes can prolong drug release time and reduce dosing frequency.
Our product Form
Octreotide Acetate COA
Indirect and direct effects of Octreotide Acetate on gut microbiota and its metabolites
Octreotide Acetate is an artificially synthesized octapeptide analogue of somatostatin that inhibits the secretion of various gastrointestinal and pancreatic hormones by mimicking the physiological effects of natural somatostatin. As a commonly used peptide drug in clinical practice, its injectable form (Octreotide Acetate Solution) is widely used in the treatment of diseases such as acromegaly, neuroendocrine tumors (such as carcinoid syndrome, VIP tumors), and severe diarrhea. In recent years, gut microbiota has become a core hub for host metabolism and immune regulation, and its mechanism of interaction with drugs has become a research hotspot. Octreotide may have a significant impact on the composition of gut microbiota and its metabolites (such as short chain fatty acids, bile acids, lipopolysaccharides, etc.) by regulating gut hormone secretion, altering the gut microenvironment, and directly acting on microbial metabolic pathways.
Pharmacological properties and mechanism of action of Octreotide Acetate
Drug chemical structure and receptor selectivity
Octreotide is an octapeptide derivative of natural somatostatin, which stabilizes its half-life through a cyclic structure (approximately 1.5 hours for intravenous injection and 2-3 hours for subcutaneous injection). Its chemical structure contains non natural amino acids such as D-phenylalanine and L-ornithine, significantly enhancing its binding affinity with the somatostatin receptor (SSTR). There are five subtypes of SSTR (SSTR1-5) in the human body, and octreotide has much higher selectivity for SSTR2 and SSTR5 than natural somatostatin. This characteristic makes it more effective and persistent in inhibiting the secretion of growth hormone (GH), glucagon, insulin, and gastrointestinal peptides.
Core pharmacological effects
Octreotide activates SSTR, inhibits adenylate cyclase activity, and reduces intracellular cAMP levels, thereby blocking the signaling pathway of hormone secretion. Its clinical indications include:
Acromegaly: Inhibiting excessive secretion of GH and reducing tumor volume;
Neuroendocrine tumors: relieve carcinoid syndrome (flushing, diarrhea), VIP tumor associated diarrhea, and glucagonoma syndrome;
Gastrointestinal and pancreatic function regulation: reduces pancreatic exocrine secretion, inhibits gastric acid secretion, and delays gastric emptying.
Metabolic and excretion pathways
Octreotide is mainly excreted through the kidneys (about 30% -40% in its original form), while the rest is metabolized through the liver. Its metabolites (such as deaminated octreotide) still retain some biological activity, but their clinical significance is limited. It is worth noting that the metabolic process of octreotide may be influenced by the gut microbiota, forming a closed loop of drug microbiota interactions.
Direct impact on gut microbiota
Direct mechanism of inhibiting bacterial growth
Nutritional competition and metabolic inhibition
Octreotide indirectly limits bacterial growth by inhibiting pancreatic enzyme secretion and reducing the availability of nutrients (such as carbohydrates and proteins) in the intestine. For example, in patients with cancer like syndrome, octreotide can lower intestinal pH and inhibit the proliferation of pathogenic bacteria that require alkaline environments, such as Clostridium perfringens. In addition, octreotide may directly inhibit key metabolic enzymes in the microbiota, such as β - glucuronidase, reducing toxin production.
Antibacterial peptide like effects
Some studies suggest that octreotide may directly disrupt bacterial cell membranes by mimicking the function of host antimicrobial peptides, such as defense factors. For example, in vitro experiments, the minimum inhibitory concentrations (MIC) of octreotide against Staphylococcus aureus and Escherichia coli were 16 μ g/mL and 32 μ g/mL, respectively, and its mechanism of action may be related to the disruption of the cell membrane lipid bilayer.
Inhibition of bacterial adhesion
Octreotide can downregulate the expression of adhesion molecules (such as integrins) on the surface of intestinal epithelial cells, reducing the colonization of pathogenic bacteria (such as Helicobacter pylori). In animal models, pre-treatment with octreotide significantly reduced the gut microbiota translocation rate after Salmonella infection.
Clinical Evidence: Changes in Microbial Composition
Patients with neuroendocrine tumors
A cohort study of patients with carcinoid syndrome showed that after 6 months of treatment with octreotide, the ratio of Firmicutes to Bacteroidetes in the gut microbiota (F/B ratio) significantly decreased, while the abundance of butyrate producing bacteria (such as Roseburia) decreased, and the relative abundance of opportunistic pathogens (such as Enterobacteriaceae) increased. This dysbiosis of the microbiota may be associated with octreotide induced decreased intestinal motility and alterations in bile acid metabolism.
Cirrhotic patients with portal hypertension
Octreotide Acetate Solution is commonly used to control bleeding from esophageal and gastric varices. Research has found that short-term use of octreotide (48 hours) can reduce gut microbiota diversity, manifested by a decrease in Bacteroidetes and an increase in Proteobacteria, which may be related to drug-induced intestinal ischemia and mucosal barrier damage.
Animal experiment verification
In an obese mouse model, octreotide intervention significantly reduced the abundance of Akkermansia muciniphila (a mucin degrading bacterium positively associated with metabolic health) in the gut, while increasing the proportion of lipopolysaccharide (LPS) producing bacteria such as Desulfovibrio. These changes are consistent with the mechanism by which octreotide inhibits mucin secretion and slows down intestinal motility.
Indirect effects on metabolites of gut microbiota
Metabolic regulation of short chain fatty acids (SCFAs)
Mechanism for Reducing SCFA Generation
SCFAs (such as acetic acid, propionic acid, and butyric acid) are the main products of dietary fiber fermented by gut microbiota, with functions of anti-inflammatory, immune regulation, and maintaining intestinal barrier integrity. Octreotide inhibits SCFA generation through the following pathways:
Inhibition of microbial fermentation ability: Octreotide reduces pancreatic enzyme secretion, lowers the availability of fermentable carbohydrates (such as starch and cellulose) in the intestine, and directly limits the substrate supply for SCFA production by the microbial community.
Change in microbial composition: Octreotide induced reduction in butyrate producing bacteria (such as Faecalibacterium prausnitzii) leads to a decrease in butyrate production. In patients with carcinoid syndrome, the concentration of fecal butyric acid decreased by 30% -40% after 6 months of treatment with octreotide.
Inhibition of mucin degradation: The reduction of mucin degrading bacteria such as Akkermansia muciniphila reduces the utilization efficiency of host mucin as a substitute carbon source, further inhibiting SCFA generation.
Clinical significance of reduced SCFA
SCFA deficiency is associated with various diseases, including:
Intestinal barrier damage: Butyric acid is the main energy source for colonic epithelial cells, and its reduction can lead to decreased expression of tight junction proteins (such as Occludin and ZO-1), increasing intestinal permeability.
Aggravated inflammatory response: SCFA inhibits the NF - κ B signaling pathway by activating the G protein coupled receptor (GPR41/43), which may promote LPS induced systemic inflammatory response.
Metabolic disorders: Propionic acid can regulate appetite through the gut brain axis, and its reduction may exacerbate gastrointestinal symptoms induced by octreotide, such as bloating and early satiety.
Bile acid (BA) metabolism regulation
Mechanism of BA cycle change
Bile acids are the end products of cholesterol metabolism, which are modified by the gut microbiota to form secondary bile acids such as deoxycholic acid and lithocholic acid. Octreotide affects BA metabolism through the following pathways:
Inhibition of bile secretion: Octreotide inhibits the secretion of cholecystokinin (CCK), reduces gallbladder emptying, and leads to a decrease in the concentration of primary bile acids (such as cholic acid and chenodeoxycholic acid) in the intestine.
Changing the activity of bile acid metabolism enzymes in the microbiota: Octreotide can downregulate the expression of 7 α - dehydroxylase (responsible for converting primary bile acids into secondary bile acids) in the intestine, reducing the production of deoxycholic acid. In animal experiments, octreotide intervention reduced the proportion of secondary bile acids in feces from 60% to 35%.
Activation of farnesol X receptor (FXR): Primary bile acids (such as bile acids) are natural ligands of FXR, and their reduction may inhibit liver bile acid synthesis through the FXR-FGF15/19 axis, forming negative feedback regulation.
Clinical significance of BA metabolic changes
BA metabolic disorders are associated with the following diseases:
Lipid absorption disorder: Bile acid deficiency leads to insufficient fat emulsification, which may exacerbate octreotide induced diarrhea and malnutrition.
Increased risk of liver injury: Secondary bile acids (such as deoxycholic acid) have cytotoxicity, and their reduction may reduce the risk of bile acid-induced hepatocyte apoptosis; But the accumulation of primary bile acids may promote liver fibrosis through FXR activation.
Aggravated dysbiosis of the microbiota: BA is an important signaling molecule that regulates the composition of the microbiota, and its proportional changes may further drive the expansion of opportunistic pathogens (such as Enterobacteriaceae).
Lipopolysaccharide (LPS) and inflammation regulation
Mechanism of increased LPS production
LPS is the main component of the cell wall of Gram negative bacteria, and its release into the bloodstream can trigger systemic inflammatory responses. Octreotide may increase LPS levels through the following pathways:
Intestinal barrier damage: Octreotide inhibits mucin secretion and SCFA production, weakens the physical barrier (such as mucus layer) and chemical barrier (such as antimicrobial peptides) of the intestine, and promotes LPS translocation.
Microbial dysbiosis: The relative abundance of LPS producing bacteria (such as Enterobacteriaceae and Bacteroidetes) induced by octreotide increases, directly increasing LPS production. In patients with cirrhosis, treatment with octreotide increases blood LPS concentration by 20% -30%.
Immunosuppression: Octreotide weakens the host's ability to clear LPS by inhibiting the expression of Toll like receptor 4 (TLR4), forming a vicious cycle of "high LPS low clearance".
Clinical significance of increased LPS
Elevated levels of LPS are associated with the following complications:
Systemic Inflammatory Response Syndrome (SIRS): In patients with neuroendocrine tumors, octreotide acetate solution induced LPS translocation may exacerbate symptoms such as flushing and diarrhea.
Insulin resistance: LPS interferes with insulin signal transduction by activating the IKK β/NF - κ B pathway, which may partially counteract the hypoglycemic effect of octreotide (although octreotide itself does not directly regulate blood glucose).
Liver injury: LPS-TLR4 axis activates Kupffer cells, releasing pro-inflammatory factors such as TNF - α and IL-6, accelerating the process of liver fibrosis.
Hot Tags: octreotide acetate solution, China octreotide acetate solution manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, adlyxin discontinued, glp1 shot, etelcalcetide structure
